Ceftaroline in vitro activity against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococci: a short report from Italy

References

• Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem. 2003;11:2427–37.
   PubMed Web of Science ®Google Scholar
• Pereira SFF, Henriques AO, Pinho MG, de Lencastre H, Tomasz A. Role of PBP1 in cell division of Staphylococcus aureus. J Bacteriol. 2007;189(9):3525–31.
   PubMed Web of Science ®Google Scholar
• Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Stafilococcus aureus and Streptococcus pneumonia. J Antimicrob Chemother. 2010;65(4):713–6.
   PubMed Web of Science ®Google Scholar
• Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumonia. Antimicrob Agents Chemother. 2010;54(5):1670–7.
   PubMed Web of Science ®Google Scholar
• Iizawa Y, Nagai J, Ishikawa T, Hashiguchi S, Nakao M, Okonogi K. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother. 2004;10:146–56.
   PubMed Web of Science ®Google Scholar
• Sader HS, Ritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49:3501–12.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC, Spangler SK, Jacobs MR. Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium. Eur J Clin Microbiol Infect Dis. 1990;9(1):47–50.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard ninth edition. Document M07-A9. Wayne, PA: CLSI 2012.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. nineteenth informational supplement. M100-S23. Wayne, PA: CLSI 2013.
   Google Scholar
• Schoenknecht FD, Sabath LD, Thornsberry C. Susceptibility tests. (ed. Lennette EH, Balows A, Hansler WJHJr, et al.). Manual of clinical microbiology. 4th edn. Washington, DC: American Society for Microbiology; 1985; p.04.
   Google Scholar
• Morrisey I, Leakey A, Blackman Northwood J. In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009. Int J Antimicrob Agents. 2012;40:227–34.
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49:3501–12.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacè-Wiens PR, Rubistein E, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69:809–31.
   PubMed Web of Science ®Google Scholar
• Iizawa Y, Nagai J, Ishikawa T, Hashiguchi S, Nakao M, Myyake A, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother. 2004;10:146–56.
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, Miegèville AF, Hamel A, Bugnon D, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother. 2007;51:3397–400.
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T9 1825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion test. J Antimicrob Chemother. 2005;56:1047–52.
   PubMed Web of Science ®Google Scholar
• Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanism of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004;38(6):864–70.
   PubMed Web of Science ®Google Scholar
• Marconescu P, Graviss EA, Musher DM. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomicin. Scand J Infect Dis. 2012;44:620–2.
   PubMed Web of Science ®Google Scholar
• Croisier-Bertin D, Piroth L, Charles PE, Larribeau A, Biek D, Ge Y, et al. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother. 2011;55(7):3557–63.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI)/National Committee for Clinical Laboratory Standards (NCCLS). Methods for detecting bactericidal activity of antimicrobial agents. Approved guideline. Document M26-A. Wayne, PA: NCCLS 1999.
   Google Scholar
• Peterson LR, Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev. 1992;5(4):420–32.
   PubMed Web of Science ®Google Scholar
• Housman ST, Sutherland CA, Nicolau DP. Pharmacodinamic profile of commonly utilized parenteral therapies against meticillin-susceptible and meticilli-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014;44:235–41.
   PubMed Web of Science ®Google Scholar